Fiona Bisshop

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

Jean van Wyk, Faïza Ajana, Fiona Bisshop et al. · Clinical Infectious Diseases · 2020 · 273 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial

Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana et al. · Clinical Infectious Diseases · 2022 · 137 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

A melanoma octamer binding protein is responsive to differentiating agents.

Richard A. Sturm, Fiona Bisshop, Hiromasa Takahashi et al. · PubMed · 1991 · 25 citations

Medicine, Molecular Biology, Oncology +9

900. Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen (TBR) in Maintaining Virologic Suppression Through 144 Weeks (TANGO Study)

Olayemi Osiyemi, Faïza Ajana, Fiona Bisshop et al. · Open Forum Infectious Diseases · 2021 · 19 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +14

HIV in practice: current approaches and challenges in the diagnosis, treatment and management of HIV infection in Australia

DE Smith, DB Russell, Fiona Bisshop et al. · HIV Medicine · 2018 · 12 citations · Full text

Public Health, Family Medicine, Clinical Medicine +12